国: アイルランド
言語: 英語
ソース: HPRA (Health Products Regulatory Authority)
FLUTICASONE PROPIONATE FORMOTEROL FUMARATE
Mundipharma Pharmaceuticals Limited
FLUTICASONE PROPIONATE FORMOTEROL FUMARATE
50/5 Microgram
Pressurised Inhalation Suspension
Product subject to prescription which may be renewed (B)
Authorised
0000-00-00
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Iffeza 50 microgram/5 microgram per metered dose pressurised inhalation, suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each metered dose (ex-valve) contains: 50 micrograms of fluticasone propionate and 5 micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator) of approximately 46 microgram of fluticasone propionate/4.5 microgram of formoterol fumarate dihydrate. For full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Pressurised inhalation, suspension The canister contains white to off white liquid suspension. The canister is in a white actuator with a grey integrated dose indicator and a light grey mouthpiece cover. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS This fixed-dose combination of fluticasone propionate and formoterol fumarate (Iffeza inhaler) is indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting 2 agonist) is appropriate: • For patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short- acting 2 agonist. Or • For patients already adequately controlled on both an inhaled corticosteroid and a long-acting 2 agonist. Iffeza 50 microgram _/_5 microgram inhaler is indicated in adults and adolescents aged 12 years and above. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology For inhalation use. Patients will need to be trained on the use of the inhaler and their asthma should be regularly reassessed by a doctor, so that the strength of Iffeza inhaler they are receiving remains optimal and is only changed on medical advice. The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. Once con 完全なドキュメントを読む